KRAKOW, Poland, April 9, 2020 /PRNewswire/ -- Ryvu Therapeutics (WSE:RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today reported its annual 2019 financial results and provided a corporate update.... |